Exenatide Lipid Formulation and Enteric Capsule Data for Oral Peptide Delivery

A 1.3 MB supplementary document from a 2026 study by Camille Dumont, shared under a CC-BY-4.0 license on figshare. It details the development of a two-tier oral delivery system for the GLP-1 analog exenatide, combining hydrophobic ion-pairing, a lipid-based formulation, and enteric capsules. The document reports specific experimental results, including a particle size of 106 nm and a drug load of 6 mg/g.

Use Cases

• Benchmarking lipid-based formulation parameters based on the reported composition of 85% Labrafac MC60, 10% Kolliphor RH40, and 5% propylene glycol.
• Analyzing the impact of hydrophobic ion-pairing on peptide lipophilicity based on the reported log P shift from -2.9 to 0.9.
• Evaluating in vitro enzymatic protection strategies for peptides based on the described α-chymotrypsin degradation tests.
• Designing enteric capsule systems for coordinated drug release based on the described gelatin/HPMC-AS capsule engineering.

Strengths

• Includes specific, quantitative experimental results such as a final particle size of 106 nm and a drug load of 6 mg/g.
• Provides detailed formulation composition percentages and molar ratios for ion-pairing.
• Document is recent, with a last update timestamp of 2026-05-22.

Limitations

• The core data is embedded in a DOCX document (1.3 MB), requiring manual extraction for computational analysis.
• Row count and column-level documentation are absent; data structure and semantics must be inferred from the text.
• The dataset's scale is small (1.3 MB), limiting the volume of directly machine-readable data.

Provenance

Source

figshare, authored by Camille Dumont.

Collection Method

Likely contains experimental data and results from a laboratory study on peptide formulation.

Freshness

Last updated 2026-05-22 05:35:24.